Abstract
In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
